065660.KQ
Anterogen.Co.,Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 14,840.00
−0.34%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.4B | 7.5B | 6.9B | 6.5B | 6.6B |
| Cost of Revenue | 5.9B | 5.2B | 4.3B | 3.8B | 4.0B |
| Gross Profit | 2.5B | 2.4B | 2.6B | 2.7B | 2.6B |
| Operating Expenses | |||||
| R&D Expense | 3.3B | 3.1B | 4.1B | 5.4B | 4.7B |
| SG&A Expense | 834.7M | 569.7M | 718.4M | 731.3M | 1.1B |
| General & Admin Expense | 107.8M | 133.8M | 192.6M | 209.6M | 804.5M |
| Selling & Marketing Expense | 335.9M | 435.9M | 525.8M | 521.6M | 317.1M |
| Other Expenses | 1.5B | 1.1B | 1.6B | 1.6B | 1.5B |
| Total Operating Expenses | 4.9B | 4.8B | 6.4B | 7.7B | 7.3B |
| Cost and Expenses | 10.8B | 10.0B | 10.7B | 11.6B | 10.8B |
| Operating Income (EBIT) | (2.5B) | (2.4B) | (3.7B) | (5.1B) | (4.6B) |
| Non-Operating | |||||
| Interest Income | 1.2B | 1.3B | 1.6B | 2.0B | 990.1M |
| Interest Expense | — | — | 259.6M | 1.5B | 1.7B |
| Net Interest Income | 1.2B | 1.3B | 1.4B | 452.7M | (704.5M) |
| Other Non-Op Income/Expense | 1.1B | 1.3B | 1.5B | 2.2B | (2.2B) |
| Non-Operating Income (excl Interest) | (80.00) | — | (1.7B) | (3.8B) | 969.0M |
| EBT (Pre-Tax Income) | (1.3B) | (1.1B) | (2.3B) | (2.8B) | (6.9B) |
| Income Tax Expense | 279.5M | 279.5M | — | — | (13.0M) |
| Bottom Line | |||||
| Net Income | (1.6B) | (1.1B) | (2.3B) | (2.8B) | (6.8B) |
| Earnings from Cont. Ops | (1.6B) | (1.1B) | (2.3B) | (2.8B) | (6.8B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.6B) | (1.1B) | (2.3B) | (2.8B) | (6.8B) |
| Per Share | |||||
| Basic EPS | (₩162) | (₩110) | (₩236) | (₩292) | (₩706) |
| Diluted EPS | (₩162) | (₩110) | (₩236) | (₩292) | (₩706) |
| Revenue Per Share | ₩836 | ₩760 | ₩712 | ₩668 | ₩680 |
| Shares | |||||
| Basic Shares Outstanding | 10.0M | 9.9M | 9.7M | 9.7M | 9.7M |
| Diluted Shares Outstanding | 10.0M | 9.9M | 9.7M | 9.7M | 9.7M |
| Profitability Metrics | |||||
| EBITDA | (1.8B) | (1.8B) | (1.6B) | (484.4M) | (4.4B) |
| D&A | 666.2M | 593.6M | 420.7M | 830.4M | 763.1M |
| EBIT | (2.5B) | (2.4B) | (2.0B) | (1.3B) | (5.2B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026